by Lina Olsson | Oct 26, 2023 | News
Swedish biotech company HiloProbe says it has reached a significant milestone after the results of a prospective multicenter study conducted in collaboration with Umeå University and eight Swedish hospitals were published in the International Journal of Cancer. The...
by Lina Olsson | Aug 23, 2023 | News
Thomas Busch has taken over as Chairman of the Board at Swedish biotech company Hiloprobe AB at what he calls “an exciting time” for the thriving business. “We are now ready to transition from a research company to actively marketing and selling our ColoNode biomarker...
by Lina Olsson | Jun 29, 2023 | News
Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode’s benefits and usefulness in colon cancer. “The results...
by Lina Olsson | May 12, 2023 | News
We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries. For more information please read Biocartis...
by Lina Olsson | Sep 29, 2022 | News
HiloProbe has participated in a major international surgeon congress in Dublin. – Surgeons are one of our main stakeholders and therefore it important to meet, discuss and present data to them, says Lina Olsson, CEO. HiloProbe participated at the well-attended...
by Lina Olsson | Feb 10, 2022 | News
HiloProbe has CE-marked the ColoNode to satisfy the needs of potential customers who want to start testing the product. – Research Use Only was not enough. Therefore, we have put a lot of focus and resources into completing CE documentation according to IVDD in...
